{
  "meta": {
    "title": "Drug_Used_In_Hypertension",
    "url": "https://brainandscalpel.vercel.app/drug-used-in-hypertension-80853592.html",
    "scrapedAt": "2025-11-29T18:33:44.542Z"
  },
  "questions": [
    {
      "id": 3801,
      "choices": [
        {
          "id": 15183,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides</span></span></span></p>"
        },
        {
          "id": 15184,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta adrenergic blocker</span></span></span></p>"
        },
        {
          "id": 15185,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACE inhibitor</span></span></span></p>"
        },
        {
          "id": 15186,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diazoxide</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with concomitant diabetes, anti-hypertensive agent of choice is? </span></span></span></p>",
      "unique_key": "Q9464287",
      "question_audio": null,
      "question_video": null,
      "map_id": 36025,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) ACE inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ACE inhibitors</strong> are the preferred choice for<strong> hypertensive patients</strong> with <strong>diabetes </strong>because they have <strong>protective effects on the kidneys,</strong> which are often compromised in diabetic patients. They <strong>reduce blood pressure and decrease the progression of diabetic nephropathy</strong> by <strong>reducing intraglomerular pressure and proteinuria.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Thiazides:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thiazide diuretics are effective <strong>antihypertensive</strong> agents but can<strong> affect carbohydrate metabolism </strong>and are <strong>not</strong> the<strong> first choice in patients with diabetes</strong>, as they can potentially <strong>worsen glycemic control.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Beta adrenergic blocker:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta-blockers <strong>can mask</strong> symptoms of <strong>hypoglycemia</strong> and may also affect <strong>lipid metabolism.</strong> Although they are<strong> effective for blood pressure control,</strong> they are<strong> not </strong>typically the<strong> first-line choice in diabetic patients</strong> unless there are<strong> other compelling indications such as heart failure or post-myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Diazoxide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Diazoxide is a<strong> vasodilator</strong> that can actually<strong> increase blood sugar levels </strong>by <strong>inhibiting insulin release </strong>from the <strong>pancreas</strong>. It is <strong>not </strong>used for routine treatment of <strong>hypertension </strong>and is certainly<strong> not the drug of choice in patients with diabetes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>appropriate choice of antihypertensive medication in patients with diabetes</strong>. <strong>ACE</strong> <strong>inhibitors offer renal protection </strong>and <strong>do not</strong> worsen <strong>glycemic control,</strong> making them a superior option for this patient population. Other properties of ACE inhibitors are also important for entrance exams.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Properties of ACE inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>C</strong>ough</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>A</strong>ngioedema</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>P</strong>rodrugs (except captopril and Lisinopril)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>T</strong>aste disturbances</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">O&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>O</strong>rthostatic hypotension (when combined with diuretics)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>P</strong>regnancy (contra- indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">R&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- bilateral&nbsp;<strong>R</strong>enal artery stenosis (contra-indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">I&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>I</strong>ncreased K+ (contra-indicated)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">-&nbsp;<strong>L</strong>ower the risk of diabetic nephropathy (Preferred drug in diabetic patients with hypertension)</span></span></span></p>",
      "correct_choice_id": 15185,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3598,
      "choices": [
        {
          "id": 14371,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
        },
        {
          "id": 14372,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
        },
        {
          "id": 14373,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
        },
        {
          "id": 14374,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the drug of choice for digoxin induced ventricular tachyarrhythmias?</span></span></span></p>",
      "unique_key": "Q4310077",
      "question_audio": null,
      "question_video": null,
      "map_id": 36012,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Lignocaine&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Lignocaine</strong> is the <strong>drug of choice</strong> for treating <strong>ventricular tachyarrhythmias</strong> induced by <strong>digoxin toxicity.</strong> It works by stabilizing the <strong>cardiac membrane</strong> and is effective in <strong>treating digoxin-induced arrhythmias</strong> <strong>without </strong>further<strong> inhibiting the AV conduction, </strong>which is often already <strong>compromised in digoxin toxicity.</strong> Its use in this context is based on its ability to selectively target the<strong> arrhythmogenic</strong> <strong>effects without exacerbating the digoxin effect</strong> on the <strong>AV node.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Quinidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinidine is an <strong>antiarrhythmic</strong> that can<strong> increase serum digoxin levels </strong>and is<strong> contraindicated in digoxin-induced arrhythmias</strong> because it may <strong>exacerbate toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While amiodarone is a<strong> versatile antiarrhythmic agent </strong>used in <strong>various types of arrhythmias</strong>, it can <strong>interact</strong> with <strong>digoxin and increase its levels</strong>, potentially <strong>worsening toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phenytoin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phenytoin is effective for <strong>ventricular arrhythmias, </strong>especially in the context of<strong> acute myocardial infarction,</strong> but it is<strong> not the first choice for digoxin-induced arrhythmias.</strong> It <strong>can be used </strong>if<strong> lignocaine is not available or contraindicated.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>appropriate management of digoxin-induced ventricular tachyarrhythmias</strong>. Recognizing <strong>lignocaine </strong>as the<strong> drug of choice </strong>in this scenario is <strong>critical for effectively addressing the cardiac toxicity </strong>associated with <strong>digoxin</strong> <strong>overdose</strong>, <strong>minimizing the risk </strong>of further <strong>cardiac complications.</strong></span></span></span></p>",
      "correct_choice_id": 14373,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3587,
      "choices": [
        {
          "id": 14327,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol</span></span></span></p>"
        },
        {
          "id": 14328,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
        },
        {
          "id": 14329,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitroglycerine</span></span></span></p>"
        },
        {
          "id": 14330,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with NYHA Class III breathlessness with a serum creatinine of 2.5 mg/dL and potassium level of 5.5 mEq/L. Which of the following drug is contraindicated?</span></span></span></p>",
      "unique_key": "Q2729165",
      "question_audio": null,
      "question_video": null,
      "map_id": 36009,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Spironolactone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Spironolactone</strong> is contraindicated in this patient due to the<strong> presence of renal failure </strong>(as indicated by a <strong>serum creatinine of 2.5 mg/dL,</strong> where<strong> normal is less than 1 mg/dL</strong>) and<strong> higher normal levels of serum potassium (5.5 mEq/L</strong>, where normal range is <strong>3.5&ndash;5.5</strong> <strong>mEq/L)</strong>. Spironolactone is a<strong> potassium-sparing diuretic</strong> and <strong>aldosterone antagonist </strong>which is beneficial in <strong>chronic heart failure</strong> <strong>(CHF) patients,</strong> particularly those with<strong> hypokalemia,</strong> as it prevents<strong> cardiac remodeling.</strong> However, it is <strong>contraindicated </strong>in the presence of <strong>deranged renal function</strong> because it could lead to the development of <strong>severe hyperkalemia</strong>. This risk remains even when the <strong>serum potassium level is high normal.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Carvedilol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as beta blockers like <strong>carvedilol </strong>are <strong>indicated in CHF and can reduce mortality.</strong> They should be <strong>started</strong> <strong>at a very low dose</strong> and gradually titrated<strong> to</strong> the <strong>target dose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Nitroglycerine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> because<strong> nitroglycerine is a vasodilator</strong> that can help<strong> reduce the workload of the heart</strong> and provide<strong> symptomatic relief in CHF.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Digoxin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as digoxin is an <strong>oral inotropic agent </strong>that can be used in <strong>chronic CHF</strong> to <strong>improve </strong>symptoms and possibly <strong>exercise capacity. </strong>Although it is excreted by kidneys but it can be used in renal failure after dose adjustment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with <strong>CHF and compromised renal function</strong> or <strong>elevated serum potassium levels</strong>,<strong> potassium-sparing diuretics</strong> like <strong>spironolactone </strong>should b<strong>e avoided </strong>due to the<strong> increased risk of severe hyperkalemia.</strong></span></span></span></p>",
      "correct_choice_id": 14328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3817,
      "choices": [
        {
          "id": 15247,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flecainide</span></span></span></p>"
        },
        {
          "id": 15248,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocainide</span></span></span></p>"
        },
        {
          "id": 15249,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide</span></span></span></p>"
        },
        {
          "id": 15250,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ibutilide</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the antiarrhythmic agent with the following mechanism of action? </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/14/whatsapp-image-2024-02-14-at-35057-pm.jpeg\" style=\"height:225px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q5340411",
      "question_audio": null,
      "question_video": null,
      "map_id": 36026,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Flecainide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The graph shows an<strong> action potential of a cardiac myocyte</strong> with a marked <strong>block of sodium channels </strong>and <strong>no change in the</strong> <strong>repolarization phase</strong>. This description is consistent with the action of<strong> Class IC antiarrhythmic drugs,</strong> which significantly<strong> slow the</strong> <strong>conduction of the cardiac impuls</strong>e through the<strong> myocardium by blocking sodium channels without </strong>affecting the <strong>duration of the</strong> <strong>action potential. Flecainide</strong> is a<strong> Class IC antiarrhythmic drug</strong> that exhibits a marked<strong> blockade of sodium channels,</strong> which <strong>slows</strong> <strong>conduction throughout the heart</strong>. It <strong>does not</strong> significantly prolong the<strong> action potential </strong>or <strong>affect repolarization</strong>, which is consistent with the graph shown.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tocainide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tocainide is a <strong>Class IB antiarrhythmic agent.</strong> Class IB drugs tend to <strong>shorten the action potential </strong>duration rather than having <strong>no change in repolarization.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Procainamide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide is <strong>a Class IA antiarrhythmic agent</strong> that <strong>not only blocks sodium channels</strong> but also has a <strong>moderate effect on repolarization,</strong> leading to a<strong> slight prolongation of the action potential,</strong> which is not depicted in the graph.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ibutilide:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ibutilide is a<strong> Class III antiarrhythmic drug</strong> that acts by <strong>prolonging repolarization</strong> through<strong> potassium channel</strong> <strong>blockade, </strong>which would <strong>lengthen the action potential, </strong>contrary to what is shown in the graph.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to recognize the <strong>electrophysiologic profiles</strong> of <strong>different classes of antiarrhythmic drugs.</strong> <strong>Class IC</strong> <strong>antiarrhythmics like flecainide </strong>are characterized by their <strong>potent sodium channel-blocking effects</strong> with <strong>minimal impact </strong>on the <strong>duration of the action potential.</strong> Understanding these properties is important for the <strong>appropriate selection and use of antiarrhythmic drugs in clinical practice.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-3-1.jpg\" style=\"height:978px; width:600px\" /></span></span></span></p>",
      "correct_choice_id": 15247,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3665,
      "choices": [
        {
          "id": 14639,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pregnancy induced hypertension</span></span></span></p>"
        },
        {
          "id": 14640,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renovascular hypertension</span></span></span></p>"
        },
        {
          "id": 14641,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">First line agent in hypertension</span></span></span></p>"
        },
        {
          "id": 14642,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Refractory hypertension</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha methyldopa is primarily used for treatment of: </span></span></span></p>",
      "unique_key": "Q7718915",
      "question_audio": null,
      "question_video": null,
      "map_id": 36022,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Pregnancy induced hypertension</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alpha methyldopa</strong> is primarily utilized for managing <strong>hypertension during pregnancy.</strong> It is considered <strong>safe for use </strong>in pregnant women when<strong> blood pressure control </strong>is necessary. As a <strong>prodrug, methyldopa </strong>is metabolized to its <strong>active form</strong>, which <strong>acts as an agonist at</strong> <strong>alpha-2 adrenergic receptors in the brain.</strong> This action leads to a<strong> decrease in central sympathetic outflow, t</strong>hereby <strong>lowering blood</strong> <strong>pressure.</strong> Its use in<strong> pregnancy-induced hypertension </strong>is due to its<strong> efficacy and safety profile for both the mother and the fetus.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Renovascular hypertension:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong> as <strong>alpha methyldopa </strong>is <strong>not </strong>the first choice of treatment for <strong>renovascular</strong> <strong>hypertension. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. First line agent in hypertension:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>because <strong>alpha methyldopa</strong> is<strong> not </strong>commonly used as a <strong>first-line treatment for</strong> <strong>essential hypertension. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Refractory hypertension:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> as <strong>alpha methyldopa</strong> is<strong> not</strong> typically reserved for <strong>refractory hypertension </strong>but could be used if other options are unsuitable.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alpha methyldopa </strong>is mainly used for the treatment of <strong>hypertension in pregnancy</strong> due to its <strong>efficacy and safety profile, </strong>acting through<strong> central mechanisms by stimulating alpha-2 adrenergic receptors.</strong></span></span></span></p>",
      "correct_choice_id": 14639,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3669,
      "choices": [
        {
          "id": 14655,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes direct relaxation of the blood vessels</span></span></span></p>"
        },
        {
          "id": 14656,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes dilatation of both arteries and veins</span></span></span></p>"
        },
        {
          "id": 14657,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Postural hypotension is not a common problem</span></span></span></p>"
        },
        {
          "id": 14658,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It increases plasma renin activity</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about hydralazine is not true?</span></span></span></p>",
      "unique_key": "Q8437876",
      "question_audio": null,
      "question_video": null,
      "map_id": 36023,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It causes dilatation of both arteries and veins</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hydralazine </strong>primarily causes<strong> arteriolar dilation </strong>rather than venous dilation, which is why option b is not true. It works by a <strong>direct</strong> <strong>action on vascular smooth muscle, </strong>leading to <strong>vasodilation</strong>. This is believed to involve the release of nitric oxide (NO) and the<strong> opening</strong> of<strong> potassium channels</strong>. The<strong> dilatory effect of hydralazine</strong> is more pronounced in <strong>arteries</strong>, which is why it<strong> does not c</strong>ommonly cause <strong>postural hypotension</strong>&mdash;a condition <strong>usually</strong> associated with<strong> venous dilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correct</strong> as<strong> hydrala</strong>zine does cause <strong>direct relaxation of blood vessels, </strong>particularly <strong>arterioles. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct </strong>because <strong>postural hypotension</strong> is <strong>not a</strong> common problem with <strong>hydralazine, </strong>as it<strong> does not</strong> significantly <strong>dilate veins. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct as vasodilators like hydralazine</strong> can cause an<strong> increase in plasma renin activity </strong>due to<strong> compensatory mechanisms</strong> following a <strong>decrease in blood pressure</strong>, such as <strong>increased sympathetic activity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hydralazine</strong> is an <strong>antihypertensive agent </strong>that predominantly causes <strong>arteriolar dilation,</strong> resulting in <strong>decreased blood pressure</strong> <strong>without </strong>significantly affecting <strong>veins or causing postural hypotension.</strong></span></span></span></p>",
      "correct_choice_id": 14656,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3696,
      "choices": [
        {
          "id": 14763,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It acts by causing a reduction in central sympathetic outflow </span></span></span></p>"
        },
        {
          "id": 14764,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It increases LDL-cholesterol on prolonged use </span></span></span></p>"
        },
        {
          "id": 14765,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sedation and xerostomia are common side effects of clonidine</span></span></span></p>"
        },
        {
          "id": 14766,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be combined with vasodilators</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements are true about the use of clonidine in the treatment of hypertension except:</span></span></span></p>",
      "unique_key": "Q1228608",
      "question_audio": null,
      "question_video": null,
      "map_id": 36028,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It increases LDL-cholesterol on prolonged use</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clonidine</strong> <strong>does not</strong> <strong>increase LDL-cholesterol</strong> with prolonged use; in fact, it is known to <strong>decrease LDL and increase HDL-cholesterol.</strong> Clonidine is an <strong>alpha-2 adrenergic agonist</strong> that acts <strong>centrally to reduce sympathetic outflow, </strong>which in turn <strong>lowers blood pressure</strong>. It is <strong>effective</strong> when used <strong>alone or in combination</strong> with other <strong>antihypertensive agents, </strong>including <strong>vasodilators. </strong>Combining <strong>clonidine</strong> with <strong>vasodilators </strong>can be particularly beneficial because it can prevent the<strong> reflex increase in renin release</strong> that <strong>vasodilators often cause.</strong> <strong>Sedation and dry mouth (xerostomia)</strong> are indeed common <strong>side effects </strong>associated with <strong>clonidine use.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Correct </strong>as <strong>clonidine decreases central sympathetic outflow</strong> due to its <strong>alpha-2 agonist action. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct</strong> since<strong> sedation and xerostomia are well-documented side effects of clonidine. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct</strong> because<strong> clonidine can be combined with vasodilators</strong> to treat <strong>hypertension effectively.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Clonidine, an alpha-2 agonist</strong>, is used in the treatment of<strong> hypertension,</strong> primarily by <strong>reducing central sympathetic outflow</strong> and <strong>not</strong> by <strong>increasing LDL-cholesterol;</strong> it actually tends to have a<strong> beneficial effect on cholesterol profiles.</strong></span></span></span></p>",
      "correct_choice_id": 14764,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3701,
      "choices": [
        {
          "id": 14783,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Atrial fibrillation</span></p>"
        },
        {
          "id": 14784,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Bradycardia with AV block</span></p>"
        },
        {
          "id": 14785,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Torsades de pointes</span></p>"
        },
        {
          "id": 14786,
          "text": "<p><span style=\"font-size:12pt;\">Tachycardia</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A patient was taking verapamil for PSVT prophylaxis. He was given propranolol for treatment of essential tremors. This combination can result in:</span></p>",
      "unique_key": "Q2136101",
      "question_audio": null,
      "question_video": null,
      "map_id": 36029,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B) Bradycardia with AV block</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Both propranolol</strong> and <strong>verapamil </strong>have <strong>negative chronotropic effects,</strong> meaning they <strong>decrease heart rate</strong>. <strong>Propranolol</strong> does this by <strong>blocking beta-1 adrenergic receptors,</strong> primarily affecting the <strong>sinoatrial (SA) node</strong>, while <strong>verapamil blocks L-type calcium channels,</strong> which are critical for <strong>impulse conduction</strong> through the <strong>atrioventricular (AV) node.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Adding <strong>verapamil </strong>to a patient already on <strong>propranolol increases the risk of additive effects</strong> on<strong> heart rate and conduction. </strong>This can lead to<strong> bradycardia, </strong>which is an <strong>abnormally slow heart rate,</strong> and in more severe cases, can <strong>progress to AV block.</strong> AV block occurs when the <strong>electrical conduction </strong>between the<strong> atria and ventricles</strong> is <strong>impaired,</strong> potentially leading to <strong>serious heart rhythm</strong> <strong>abnormalities </strong>and symptoms such as <strong>dizziness and fatigue.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Atrial fibrillation</strong> is <strong>not</strong> the most likely <strong>outcome </strong>of adding <strong>verapamil to propranolol </strong>therapy, although <strong>verapamil is</strong> sometimes used<strong> to control ventricular rate </strong>in patients with <strong>atrial fibrillation.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Torsades</strong> de pointes is a<strong> specific type of ventricular tachycardia</strong> often associated with a<strong> prolonged QT interval</strong>, which is <strong>not a typical side effect </strong>of either <strong>propranolol or verapamil.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Tachycardia</strong>, or<strong> increased heart rate</strong>, would be <strong>unlikely as both drug</strong>s work to<strong> slow the heart rate.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objectives:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Therefore, the most appropriate answer in the context of this clinical scenario is<strong>&nbsp;B. Bradycardia</strong> with <strong>AV block, </strong>considering the <strong>pharmacological actions of both propranolol and verapamil</strong> and the <strong>symptoms </strong>reported by the patient.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ref: KDT 8th/160</strong></span></p>",
      "correct_choice_id": 14784,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3726,
      "choices": [
        {
          "id": 14883,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Aliskiren</span></p>"
        },
        {
          "id": 14884,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Digoxin</span></p>"
        },
        {
          "id": 14885,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Ivabradine</span></p>"
        },
        {
          "id": 14886,
          "text": "<p><span style=\"font-size:12pt;\">Valsartan</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 72-year-old woman with a history of ischemic cardiomyopathy and left ventricular ejection fraction of 35%. She is NYHA class II in terms of symptoms. She is on lisinopril, carvedilol, and spironolactone. Her blood pressure is 102/82 mmHg, and heart rate is 80 bpm. Which of the following additional medications will further reduce her risk of hospitalization due to heart failure?</span></p>",
      "unique_key": "Q7749385",
      "question_audio": null,
      "question_video": null,
      "map_id": 36013,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. C) Ivabradine</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ivabradine </strong>is an appropriate choice for this patient because it <strong>reduces heart rate without </strong>causing <strong>myocardial depression</strong>. It works by selectively<strong> inhibiting the If (funny) channels in the sinoatrial node,</strong> which are responsible for <strong>regulating heart rate. </strong>In patients with <strong>heart failure</strong> who are in <strong>sinus rhythm</strong> with a<strong> heart rate of 70 bpm or higher,</strong> despite optimal treatment with <strong>beta-blockers </strong>or those who are <strong>intolerant to beta-blockers, ivabradine has been</strong> shown to <strong>reduce hospitalization </strong>due to<strong> heart failure</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Aliskiren:&nbsp;</strong>Aliskiren is a <strong>direct renin inhibitor</strong> and is used to treat<strong> hypertension. </strong>While it can <strong>reduce blood pressure</strong> and has been studied in<strong> heart failure</strong>, it is<strong> not </strong>specifically indicated to <strong>reduce mortality in heart failure patients</strong>, particularly when already on optimal therapy with an <strong>ACE inhibitor, beta-blocker, and aldosterone antagonist.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. Digoxin:</strong> Digoxin may help <strong>improve </strong>symptoms and<strong> reduce hospitalizations</strong> by <strong>increasing contractility and controlling heart rate, </strong>but it<strong> has not </strong>been shown to<strong> reduce mortality in heart failure patients.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Valsartan:&nbsp;</strong>The patient is already on <strong>lisinopril, an ACE inhibitor, </strong>which provides the <strong>mortality benefit of inhibiting the renin-angiotensin-aldosterone system (RAAS). </strong>Adding another RAAS inhibitor like <strong>valsartan, an ARB, without removing the ACE inhibitor </strong>is <strong>not </strong>typically recommended due to <strong>increased risk of adverse effects without additional mortality benefit.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ivabradine </strong>can be used in <strong>certain heart failure </strong>patients with a <strong>high heart rate </strong>despite optimal standard therapy to further <strong>reduce the risk of heart failure-related morbidity. </strong>It is important to <strong>recognize the therapeutic benefits</strong> and<strong> limitations of</strong> <strong>additional heart failure</strong> treatments in the context of a patient's overall medical regimen and clinical status.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: CMDT 2022 Pg 410</strong></span></p>",
      "correct_choice_id": 14885,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3768,
      "choices": [
        {
          "id": 15051,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chlorthalidone</span></span></span></p>"
        },
        {
          "id": 15052,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamterene</span></span></span></p>"
        },
        {
          "id": 15053,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
        },
        {
          "id": 15054,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preferred drug for the treatment of uncomplicated grade 2 hypertension in a 48-year-old man is? </span></span></span></p>",
      "unique_key": "Q1827121",
      "question_audio": null,
      "question_video": null,
      "map_id": 36019,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Chlorthalidone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chlorthalidone</strong> is a <strong>thiazide-like diuretic</strong> that is often preferred for the initial treatment of <strong>hypertension</strong>, including <strong>grade 2</strong> <strong>hypertension, </strong>which is defined as a<strong> systolic blood pressure of 140-159 mmHg or a diastolic blood pressure of 90-99 mmHg</strong>. <strong>Chlorthalidone </strong>helps to <strong>lower blood pressure by promoting the excretion of sodium and water</strong>, which<strong> reduces the volume of fluid in the blood vessels and lowers blood pressure</strong>. Its <strong>long half-life </strong>and evidence for <strong>reducing cardiovascular outcomes </strong>make it a suitable option for managing <strong>uncomplicated hypertension.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Triamterene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Triamterene is a<strong> potassium-sparing diuretic</strong> that is<strong> not</strong> typically used as <strong>first-line treatment for hypertension.</strong> It is often<strong> used in combination</strong> with other <strong>diuretics to prevent hypokalemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Spironolactone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spironolactone is another <strong>potassium-sparing diuretic </strong>that also<strong> blocks the effects of aldosterone</strong>. While it can be used for <strong>hypertension</strong>, it is usually reserved for cases that are <strong>resistant to other treatments </strong>or for <strong>specific conditions like</strong> <strong>primary hyperaldosteronism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Furosemide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Furosemide is a<strong> loop diuretic</strong> that is primarily used for the treatment of <strong>edema associated with heart failure</strong> or <strong>renal disease.</strong> It is<strong> not</strong> typically used as<strong> first-line treatment for uncomplicated hypertension</strong> due to its<strong> shorter duration of action and </strong>greater risk for<strong> electrolyte imbalances.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to identify the preferred <strong>initial treatment</strong> options for <strong>hypertension. </strong>Thiazide-like diuretics such as <strong>chlorthalidone are recommended as first-line therapy</strong> for most patients with<strong> hypertension</strong> due to their effectiveness in<strong> lowering</strong> <strong>blood pressure and reducing the risk of cardiovascular events. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FIRST LINE DRUGS FOR DIFFERENT PATIENTS WITH HYPERTENSION</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-114419.png\" style=\"height:330px; width:1000px\" /></span></strong></span></span></p>",
      "correct_choice_id": 15051,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3771,
      "choices": [
        {
          "id": 15063,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spontaneous hydrolysis</span></span></span></p>"
        },
        {
          "id": 15064,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rapid metabolism by enzymes in the liver</span></span></span></p>"
        },
        {
          "id": 15065,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uptake in RBC and endothelial cells</span></span></span></p>"
        },
        {
          "id": 15066,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal excretion</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Why does adenosine have a short half-life?</span></span></span></p>",
      "unique_key": "Q3482530",
      "question_audio": null,
      "question_video": null,
      "map_id": 36020,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Uptake in RBC and endothelial cells</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosine is known to be the shortest-acting anti-arrhythmic drug with a half-life of less than 10 seconds. Its brief duration of action is primarily attributed to its rapid uptake by red blood cells (RBCs) and endothelial cells. Once inside these cells, adenosine is quickly metabolized through two main pathways: phosphorylation and deamination. Phosphorylation, mediated by adenosine kinase, converts adenosine into adenosine monophosphate (AMP), which can then enter various pathways to be used as cellular energy. Deamination, on the other hand, is facilitated by the enzyme adenosine deaminase, leading to the production of inosine, which is further broken down into xanthine and eventually uric acid. The efficient intracellular metabolism of adenosine in these cells ensures that it does not remain active in the bloodstream for long, which is why it has such a short half-life.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spontaneous hydrolysis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While spontaneous hydrolysis can occur, it is not the primary reason for adenosine&#39;s short half-life in vivo.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Rapid metabolism by enzymes in the liver:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Although liver enzymes play a role in drug metabolism, in the case of adenosine, the rapid uptake and metabolism by RBCs and endothelial cells are more significant.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Renal excretion:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While renal excretion does remove substances from the blood, adenosine&#39;s short half-life is due more to cellular uptake and metabolism than to excretion by the kidneys.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosine has a short half-life due to rapid uptake and intracellular metabolism in RBCs and endothelial cells, where it is phosphorylated to AMP or deaminated to eventually form uric acid. Adenosine is also the drug of choice (DOC) for the treatment of paroxysmal supraventricular tachycardia (PSVT).</span></span></span></p>",
      "correct_choice_id": 15065,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3791,
      "choices": [
        {
          "id": 15143,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">a &amp; b</span></span></span></p>"
        },
        {
          "id": 15144,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">b &amp; c</span></span></span></p>"
        },
        {
          "id": 15145,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">c &amp; d</span></span></span></p>"
        },
        {
          "id": 15146,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">b &amp; d</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drug obtained from plant (shown in the Figure) is used for treatment of?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/30/picture4_rOVLeTF.jpg\" style=\"height:244px; width:302px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:lower-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Myocardial infarction</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malaria</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congestive heart failure</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Arrhythmias</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>",
      "unique_key": "Q5735148",
      "question_audio": null,
      "question_video": null,
      "map_id": 36021,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) b &amp; d</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image is identified as depicting the <strong>bark of the cinchona plant</strong>. From this plant, two significant drugs are derived: <strong>quinine and</strong> <strong>quinidi</strong>ne. Quinine has a<strong> long history </strong>of use in the treatment of <strong>malaria due to its antiprotozoal properties</strong> that are effective<strong> against</strong> the <strong>Plasmodium parasites causing the disease</strong>. <strong>Quinidine,</strong> a <strong>stereoisomer of quinine</strong>, is <strong>utilized </strong>in the <strong>medical field for its</strong> <strong>antiarrhythmic properties</strong> to treat various<strong> cardiac arrhythmias</strong> by acting on the <strong>heart&#39;s electrical conduction system </strong>to <strong>restore</strong> <strong>normal rhythm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Myocardial infarction:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Neither <strong>quinine nor quinidine </strong>is primarily used for the treatment of <strong>myocardial infarction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Malaria:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Quinine</strong>, obtained from the <strong>cinchona bark</strong>, is indeed used for the<strong> treatment of malaria.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Congestive heart failure:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Neither quinine nor quinidine</strong> is a <strong>first-line</strong> treatment for<strong> congestive heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinine and quinidine, </strong>drugs derived from the<strong> cinchona plant,</strong> are used in the treatment of<strong> malaria and cardiac arrhythmias,</strong> respectively, illustrating the<strong> importance of plant-based compounds</strong> in the <strong>development of medications.</strong></span></span></span></p>",
      "correct_choice_id": 15146,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3841,
      "choices": [
        {
          "id": 15343,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It should be given in low doses to prevent hyperkalemia</span></span></span></p>"
        },
        {
          "id": 15344,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It affords prognostic benefit in severe heart failure over and above ACEI</span></span></span></p>"
        },
        {
          "id": 15345,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It helps to overcome refractoriness to loop diuretics</span></span></span></p>"
        },
        {
          "id": 15346,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It affords rapid symptomatic relief in CHF patients</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following about the use of spironolactone in congestive heart failure are true except?</span></span></span></p>",
      "unique_key": "Q4404975",
      "question_audio": null,
      "question_video": null,
      "map_id": 36008,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) It affords rapid symptomatic relief in CHF patients</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> not typically true</strong>. While <strong>spironolactone </strong>can help manage symptoms of<strong> CHF by reducing fluid overload</strong> due to its <strong>diuretic effect,</strong> it <strong>does not</strong> provide rapid <strong>symptomatic relief.</strong> The primary effects of <strong>spironolactone in CHF</strong> are seen over a<strong> longer</strong> term, where it helps to manage<strong> fluid retention and provides benefits in terms of morbidity and mortality.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Based on these points, the statement that is <strong>not true</strong> about the <strong>use of spironolactone in CHF</strong> is <strong>d. It affords rapid symptomatic relief in CHF patients</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>It should be given in low doses to prevent hyperkalemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> true.</strong> Spironolactone is a<strong> potassium-sparing diuretic</strong>, and one of its potential side effects is <strong>hyperkalemia (high blood potassium levels). </strong>Therefore, it is typically started at a<strong> low dose to minimize this risk.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>It affords prognostic benefit in severe HF over and above ACEI.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is<strong> true</strong>. Spironolactone has been shown to provide a<strong> prognostic benefit </strong>in patients with <strong>severe heart</strong> <strong>failure, reducing morbidity and mortality</strong> when added to <strong>standard therapy, including ACE inhibitors (ACEIs).</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>It helps to overcome refractoriness to loop diuretics.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Spironolactone can be used in <strong>combination with loop diuretics </strong>to overcome <strong>diuretic resistance </strong>in <strong>CHF</strong>. L<strong>oop diuretics </strong>can lead to<strong> increased renal potassium and magnesium loss, </strong>and adding a <strong>potassium-sparing agent</strong> like<strong> spironolactone </strong>can help<strong> counteract this effect and enhance diuretic response.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Current evidence suggests the following regarding aldosterone receptor antagonist (spironolactone and eplerenone) therapy in CHF:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is indicated as<strong> add-on therapy to ACE inhibitors + other drugs</strong> in <strong>moderate-to-severe CHF.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can <strong>retard disease progression, reduce episodes of decompensation and death </strong>due to<strong> heart failure</strong> as well as <strong>sudden</strong> c<strong>ardiac deaths</strong>, over and above the <strong>protection afforded by ACE inhibitors/ARBs &plusmn; &beta; blockers.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only <strong>low doses (12.5&ndash;25 mg/day) </strong>of spironolactone should be used to <strong>avoid hyperkalemia;</strong> particularly because of <strong>concurrent ACE inhibitor/ARB therapy.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It may help <strong>restoration of diuretic response to furosemide</strong> when <strong>refractoriness has developed.</strong></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 15346,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3846,
      "choices": [
        {
          "id": 15363,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction of after load</span></span></span></p>"
        },
        {
          "id": 15364,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction of heart rate and cardiac MVO2</span></span></span></p>"
        },
        {
          "id": 15365,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduction of preload and cardiac MVO2</span></span></span></p>"
        },
        {
          "id": 15366,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increase preload with decrease in cardiac MVO2</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac oxygen demand (MVO2) must be reduced in angina pectoris. The therapeutic rationale for using SL nitroglycerine is based on: </span></span></span></p>",
      "unique_key": "Q3997576",
      "question_audio": null,
      "question_video": null,
      "map_id": 36010,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Reduction of preload and cardiac MVO2</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sublingual (SL) nitroglycerine</strong> acts primarily by<strong> dilating venous capacitance vessels,</strong> leading to a <strong>reduction in preload. </strong>By<strong> reducing preload, nitroglycerine decreases ventricular filling pressure and volume</strong>, which in turn <strong>reduces myocardial</strong> <strong>oxygen demand (MVO2</strong>). This mechanism helps <strong>alleviate angina pectoris by decreasing the workload </strong>on the heart and<strong> improving myocardial oxygen supply-demand balance.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Reduction of afterload:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While <strong>nitroglycerine</strong> may have<strong> some effect</strong> on<strong> reducing afterload </strong>due to its <strong>arterial vasodilatory</strong> <strong>properties</strong>, its<strong> primary mechanism of action</strong> is the <strong>reduction of preload.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Reduction of heart rate and cardiac MVO2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Nitroglycerine</strong> may have a <strong>mild effect on heart rate</strong>, but its primary mechanism of action is<strong> not related to heart rate reduction.</strong> It mainly <strong>reduces preload,</strong> which <strong>indirectly decreases cardiac MVO2.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Increase preload with decrease in cardiac MVO2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Increasing preload </strong>would typically <strong>increase cardiac workload and</strong> <strong>oxygen demand </strong>rather than<strong> decrease it. </strong>This option <strong>contradicts</strong> the therapeutic rationale for using <strong>nitroglycerine in angina pectoris.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>therapeutic rationale </strong>for using <strong>sublingual nitroglycerine</strong> in the management of<strong> angina</strong> <strong>pectoris</strong>. By<strong> reducing preload, </strong>nitroglycerine <strong>decreases myocardial oxygen demand,</strong> <strong>providing symptomatic relief</strong> in patients with <strong>angina</strong>. Understanding the <strong>mechanisms of action of nitroglycerine</strong> is essential for appropriate<strong> prescribing and management</strong> of <strong>angina episode</strong>s.</span></span></span></p>",
      "correct_choice_id": 15365,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3821,
      "choices": [
        {
          "id": 15263,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These should be started at a very low dose and slowly titrated upwards</span></span></span></p>"
        },
        {
          "id": 15264,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol is the most widely used &beta; blocker</span></span></span></p>"
        },
        {
          "id": 15265,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These are drug of choice in acute decompensated heart failure</span></span></span></p>"
        },
        {
          "id": 15266,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These can reduce mortality in CHF patients</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT true about the use of &beta; blockers in CHF?</span></span></span></p>",
      "unique_key": "Q3002626",
      "question_audio": null,
      "question_video": null,
      "map_id": 36027,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) These are drug of choice in acute decompensated heart failure</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta blockers</strong> are not the drug of choice in<strong> acute decompensated heart failure.</strong> In fact, they are <strong>contraindicated</strong> in this condition due to <strong>their potential to worsen the hemodynamic status.</strong> In <strong>acute decompensated heart failure</strong>, the goal is to<strong> quickly improve cardiac</strong> <strong>output and relieve symptoms,</strong> and the<strong> negative inotropic effects of beta blockers </strong>can <strong>counteract this goal.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. These should be started at a very low dose and slowly titrated upwards:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>correct </strong>and a key principle in the <strong>chronic</strong> management of <strong>CHF</strong>. Beta blockers need to be started at<strong> low doses to avoid abrupt changes in cardiac function</strong> and allow for patient tolerance.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Carvedilol is the most widely used &beta; blocker:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>carvedilol </strong>is one of the commonly used <strong>beta blockers in CHF,</strong> saying it is &quot;<strong>the most widely used</strong>&quot; may <strong>not be true in all settings,</strong> as <strong>metoprolol and bisoprolol </strong>are<strong> also commonly prescribed.</strong> However, this statement is generally accepted in practice.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. These can reduce mortality in CHF patients:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>true</strong>. <strong>Beta blockers</strong> have been shown to<strong> decrease mortality in chronic</strong> <strong>CHF </strong>by <strong>improving left ventricular function</strong>, <strong>reducing arrhythmias, and limiting cardiac remodeling.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><strong><u> </u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta blockers</strong> should <strong>not</strong> be used as the <strong>drug of choice</strong> in <strong>acute decompensated heart failure</strong> but are essential for the management of<strong> chronic CHF</strong>, where they have been shown to <strong>reduce mortality and morbidity.</strong></span></span></span></p>",
      "correct_choice_id": 15265,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3583,
      "choices": [
        {
          "id": 14311,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Losartan</span></span></span></p>"
        },
        {
          "id": 14312,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Telmisartan</span></span></span></p>"
        },
        {
          "id": 14313,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Candesartan</span></span></span></p>"
        },
        {
          "id": 14314,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Olmesartan</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angiotensin receptor blocker which blocks thromboxane A2 receptor is?</span></span></span></p>",
      "unique_key": "Q3535972",
      "question_audio": null,
      "question_video": null,
      "map_id": 36030,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Losartan</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Losartan </strong>is the correct answer because it is<strong> not </strong>only an <strong>angiotensin receptor blocker (ARB)</strong> but also a <strong>competitive antagonist </strong>of the <strong>thromboxane A2 receptor</strong>. This <strong>dual action means</strong> that<strong> Losartan can block the effects of thromboxane A2</strong>, leading to an <strong>attenuation</strong> of <strong>platelet aggregation</strong>. Additionally, the<strong> metabolite of Losartan</strong> has the ability to <strong>reduce COX-2 mRNA upregulation</strong> and <strong>COX-dependent prostaglandin generation,</strong> which further contributes to its<strong> antiplatelet effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Telmisartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor</strong> <strong>gamma (PPAR-&gamma;),</strong> which differentiates it from Losartan and <strong>does not</strong> confer the ability to<strong> block the thromboxane A2 receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Candesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>Candesartan </strong>is an <strong>inactive ester </strong>prodrug that <strong>does not</strong> possess the ability to <strong>block the</strong> <strong>thromboxane A2 receptor.</strong> It is<strong> hydrolyzed</strong> to<strong> its active form </strong>within the body, which <strong>acts selectively </strong>on the<strong> angiotensin receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Olmesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> for this question since <strong>Olmesartan, </strong>while also being an<strong> inactive ester prodrug hydrolyzed </strong>to its <strong>active form</strong>, <strong>does not block the thromboxane A2 receptor.</strong> It is <strong>cleared by renal elimination</strong> and<strong> biliary excretion</strong> and <strong>does not</strong> require dose adjustment in patients with <strong>mild-to-moderate renal or hepatic impairment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Losartan</strong> is unique among <strong>angiotensin receptor blockers </strong>in that it also <strong>competitively antagonizes</strong> the <strong>thromboxane A2 receptor,</strong> contributing to its <strong>antiplatelet effects.</strong></span></span></span></p>",
      "correct_choice_id": 14311,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3850,
      "choices": [
        {
          "id": 15379,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aliskiren</span></span></span></p>"
        },
        {
          "id": 15380,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Losartan</span></span></span></p>"
        },
        {
          "id": 15381,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Perindopril</span></span></span></p>"
        },
        {
          "id": 15382,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vernakalant</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a direct renin inhibitor? </span></span></span></p>",
      "unique_key": "Q4577835",
      "question_audio": null,
      "question_video": null,
      "map_id": 36011,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Aliskiren</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aliskiren is a novel class of antihypertensive drug</strong> that works by directly<strong> inhibiting renin,</strong> an enzyme responsible for the conversion of <strong>angiotensinogen to angiotensin I (Ang I).</strong> This action effectively <strong>inhibits the renin-angiotensin-aldosterone system (RAAS)</strong> at its <strong>earliest step</strong>. Aliskiren is a<strong> low-molecular-weight, non-peptide molecule</strong> that acts as a <strong>potent competitive inhibitor of renin, reducing the production of angiotensin II (Ang II)</strong> as a result of the <strong>blocked conversion of angiotensinogen to Ang I.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Losartan:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Losartan is an<strong> angiotensin II receptor blocker (ARB),</strong> which works further<strong> downstream in the RAAS pathway </strong>by <strong>blocking the angiotensin II type 1 receptors on blood vessels,</strong> leading to<strong> vasodilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Perindopril:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Perindopril is an <strong>angiotensin-converting enzyme (ACE) inhibitor</strong>. It <strong>prevents </strong>the conversion of <strong>angiotensin I to</strong> <strong>angiotensin II </strong>by inhibiting the <strong>ACE enzyme.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Vernakalant:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Vernakalant is<strong> not </strong>related to the <strong>RAAS pathway</strong>; it is a<strong> class III antiarrhythmic agent</strong> that acts as a <strong>multiple</strong> <strong>ion channel blocke</strong>r, particularly affecting<strong> atrial cells, </strong>and is used to treat certain<strong> types of arrhythmias.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aliskiren</strong> is the only direct <strong>renin inhibitor </strong>among the options listed, acting at the<strong> rate-limiting step of the RAAS pathway</strong> by <strong>inhibiting the conversion of angiotensinogen to angiotensin I.</strong></span></span></span></p>",
      "correct_choice_id": 15379,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3862,
      "choices": [
        {
          "id": 15427,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine</span></span></span></p>"
        },
        {
          "id": 15428,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol </span></span></span></p>"
        },
        {
          "id": 15429,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretic </span></span></span></p>"
        },
        {
          "id": 15430,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 33-year-old man is diagnosed with essential hypertension. He is started on an anti-hypertensive medication. After 6 weeks, he notes fatigue, rash over his face, joint aches, and effusions. A serum antinuclear antibody (ANA) test is positive. Which of the following is the most likely agent person was prescribed? </span></span></span></p>",
      "unique_key": "Q4786450",
      "question_audio": null,
      "question_video": null,
      "map_id": 36014,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hydralazine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s symptoms of <strong>fatigue, malar rash, joint pain, effusions</strong>, and a <strong>positive ANA test </strong>suggest the development of a<strong> drug-induced lupus erythematosus (SLE) </strong>like syndrome.<strong> Hydralazine</strong> is known to be associated with the <strong>development of drug-induced SLE.</strong> The condition is<strong> similar to idiopathic SLE </strong>and includes symptoms such as those described. <strong>Drug-induced SLE is reversible </strong>on <strong>stopping</strong> the<strong> offending agent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Propranolol:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Beta-blockers</strong> like propranolol are <strong>not </strong>commonly associated with inducing a<strong> lupus-like syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Thiazide diuretic:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretics have <strong>various side effects</strong> but are<strong> not </strong>typically known to cause <strong>drug-induced lupus.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.&nbsp; Nifedipine:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine, a<strong> calcium channel blocker</strong>, is <strong>not </strong>associated with <strong>lupus-like symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hydralazine</strong> is associated with the<strong> development of a lupus-like syndrome, </strong>which is characterized by symptoms such as<strong> rash, joint</strong> <strong>pain, fatigue, and positive ANA,</strong> and it is <strong>one of the drugs</strong> that can<strong> induce</strong> this condition, summarized by the acronym <strong>&quot;SHIP&quot;</strong> for <strong>sulfonamides, hydralazine, isoniazid, and procainamide.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The drugs causing <strong>SLE like syndrome</strong> include:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">S: S</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ulfonamides (including dapsone)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">H: H</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ydralazine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I: I</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">soniazid</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P: P</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">rocainamide</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All<strong> SHIP drugs</strong> are <strong>metabolized by acetylation.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
      "correct_choice_id": 15427,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3868,
      "choices": [
        {
          "id": 15451,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamterene </span></span></span></p>"
        },
        {
          "id": 15452,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atenolol</span></span></span></p>"
        },
        {
          "id": 15453,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin</span></span></span></p>"
        },
        {
          "id": 15454,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">KCI</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient on digoxin therapy had a level of 1 ng/ml. He was receiving several other drugs and presented 2 months later with flattening of T waves in ECG. Now the plasma level of digoxin is 3.8 ng/ml. Which of the following drug is likely to be responsible? </span></span></span></p>",
      "unique_key": "Q8840588",
      "question_audio": null,
      "question_video": null,
      "map_id": 36016,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Clarithromycin</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin is a<strong> macrolide antibiotic </strong>known to <strong>inhibit the P-glycoprotein transporter, </strong>which plays a role in the <strong>renal excretion of</strong> <strong>digoxin.</strong> <strong>Inhibition</strong> <strong>of </strong>this transporter <strong>leads to decreased renal clearance of digoxin,</strong> resulting in <strong>elevated plasma levels</strong> and <strong>potential digoxin toxicity. Flattening </strong>of <strong>T waves</strong> on ECG is a common manifestation of <strong>digoxin toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Triamterene:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triamterene is a <strong>potassium-sparing diuretic </strong>that can <strong>increase digoxin levels</strong> by <strong>reducing its renal clearance.</strong> However, the<strong> extent of increase</strong> observed in this case is <strong>less </strong>commonly associated with <strong>triamterene.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Atenolol:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atenolol, a<strong> beta-blocker, </strong>can<strong> increase digoxin levels </strong>by <strong>delaying its elimination</strong>. However, the <strong>degree of increase</strong> seen here is less characteristic of atenolol&#39;s interaction with digoxin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. KCl:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Potassium chloride supplementation </strong>can potentiate the effects of <strong>digoxin</strong>, potentially leading to<strong> toxicity. </strong>However, it typically <strong>does not </strong>cause such a significant<strong> increase in digoxin levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recognizing <strong>drug interactions</strong> that impact <strong>digoxin levels</strong> is crucial for <strong>preventing digoxin toxicity </strong>in patients receiving<strong> concurrent</strong> <strong>therapy</strong>.<strong> Vigilance </strong>and <strong>close monitoring of digoxin levels </strong>are essential to ensure <strong>patient safety.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">INTERACTIONS OF DIGOXIN</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hypokalemia, hypomagnesemia, and hypercalcemia</strong> may precipitate digoxin toxicity.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs <strong>causing digoxin</strong> <strong>toxicity</strong> include:</span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Verapamil</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clarithromycin</span></span></span></li>\r\n</ul>\r\n\r\n<ol start=\"3\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Renal failure </strong>predisposes to<strong> digoxin toxicity.</strong></span></span></span></li>\r\n</ol>",
      "correct_choice_id": 15453,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3869,
      "choices": [
        {
          "id": 15455,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methyldopa</span></span></span></p>"
        },
        {
          "id": 15456,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Labetalol</span></span></span></p>"
        },
        {
          "id": 15457,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lisinopril</span></span></span></p>"
        },
        {
          "id": 15458,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nifedipine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year-old female came to hospital for preconception counseling. Patient is a known hypertensive compliant to drug therapy. Which of the following drugs will you advise to stop?</span></span></span></p>",
      "unique_key": "Q3371532",
      "question_audio": null,
      "question_video": null,
      "map_id": 36017,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Lisinopril</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ACE Inhibitors (like lisinopril) and ARBs (like telmisartan) </strong>are known to be<strong> teratogenic </strong>and should be <strong>avoided if pregnancy </strong>is under <strong>consideration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Methyldopa:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Methyldopa is<strong> commonly used in pregnancy for hypertension </strong>and is considered<strong> safe. </strong>It is often continued during pregnancy if the patient is<strong> well-controlled.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Labetalol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Labetalol is another <strong>antihypertensive agent </strong>commonly used<strong> during pregnancy</strong>. It has a<strong> good safety profile</strong> and is often continued if the <strong>patient is well-controlled.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Nifedipine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nifedipine is also considered<strong> safe for use during pregnancy </strong>and is commonly <strong>prescribed for hypertension </strong>in <strong>pregnant women.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the <strong>safety profiles of antihypertensive medications </strong>during <strong>pregnancy</strong> is essential for <strong>preconception counseling.</strong> <strong>Lisinopril is contraindicated during pregnancy</strong> due to its association with <strong>fetal malformations,</strong> particularly during the <strong>second and</strong> <strong>third trimesters</strong>. It is important to<strong> discontinue</strong> potentially<strong> harmful medications before conception</strong> to<strong> minimize risks to both </strong>the <strong>mother and the developing fetus.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SAFE ANTI-HYPERTENSIVES IN PREGNANCY</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">etter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;<strong>B</strong>eta blockers (Cardio selective and Labetalol)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">M</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">other&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;<strong>Methyldopa</strong> </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -<strong>C</strong>lonidine </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">uring&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -<strong>D</strong>ihydropyridine CCB (sustained release nifedipine, amlodipine)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">H</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ypertensive&nbsp;&nbsp; -&nbsp;<strong>H</strong>ydralazine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">regnancy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;<strong>P</strong>razosin (and other alpha blockers)</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 15457,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3755,
      "choices": [
        {
          "id": 14999,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
        },
        {
          "id": 15000,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
        },
        {
          "id": 15001,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ciprofloxacin</span></span></span></p>"
        },
        {
          "id": 15002,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can result in prolongation of QT interval in ECG?</span></span></span></p>",
      "unique_key": "Q1108176",
      "question_audio": null,
      "question_video": null,
      "map_id": 36018,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Quinidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinidine</strong> is a<strong> class Ia anti-arrhythmic drug</strong> that acts by<strong> blocking Na+ (sodium) and K+ (potassium) channels</strong>. The blocking of <strong>potassium channels </strong>is particularly important in the context of the question as it can affect the<strong> repolarization phase of the cardiac</strong> <strong>action potential, </strong>which is reflected as<strong> QT interval on an electrocardiogram (ECG). Prolonged repolarization</strong> leads to a<strong> prolonged QT</strong> <strong>interval</strong>, which can predispose to a <strong>type of ventricular tachycardia</strong> called <strong>Torsades de Pointes</strong>, a potentially <strong>life-threatening</strong> <strong>condition.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Lignocaine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (also known as lidocaine) is a<strong> class Ib anti-arrhythmic drug</strong> that predominantly <strong>blocks Na+ channels</strong> and is<strong> less </strong>likely to cause <strong>QT prolongation </strong>as its action is<strong> more specific to the fast sodium channels</strong> and it actually tends to <strong>shorten the action potential duration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ciprofloxacin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ciprofloxacin is a <strong>fluoroquinolone antibiotic</strong>. Although fluoroquinolones like <strong>sparfloxacin, levofloxacin, and</strong> <strong>moxifloxacin</strong> are associated with <strong>QT prolongation, ciprofloxacin is less</strong> implicated in causing this <strong>adverse effect</strong> when compared to other drugs in its class.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Propranolol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol is a<strong> non-selective beta-blocker</strong> and is <strong>not</strong> commonly associated with<strong> QT prolongation</strong>. It acts on the <strong>beta-adrenergic receptors </strong>and can affect<strong> heart rate and contractility</strong> but <strong>not</strong> typically the <strong>QT interval.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Quinidine,</strong> a <strong>class Ia anti-arrhythmic drug</strong>, can cause<strong> QT interval prolongation on an ECG</strong> due to its<strong> blockade of potassium channels,</strong> which affects the<strong> repolarization phase of the cardiac action potential.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-113043.png\" style=\"height:486px; width:1000px\" /></span></span></span></p>",
      "correct_choice_id": 14999,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3798,
      "choices": [
        {
          "id": 15171,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha 1</span></span></span></p>"
        },
        {
          "id": 15172,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha 2</span></span></span></p>"
        },
        {
          "id": 15173,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta 1</span></span></span></p>"
        },
        {
          "id": 15174,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta 2</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Inotropic drugs act by stimulating which of the following receptors? </span></span></span></span></span></p>",
      "unique_key": "Q4079299",
      "question_audio": null,
      "question_video": null,
      "map_id": 36024,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Beta 1</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Inotropic drugs</strong> often act by <strong>stimulating beta 1 adrenergic receptors</strong>. Beta 1 receptors are <strong>primarily found in the heart, </strong>and when they are stimulated, they<strong> increase myocardial contractility </strong>(the <strong>force of contraction</strong>) and <strong>heart rate. </strong>This <strong>action is beneficial </strong>in treating certain conditions like <strong>heart failure,</strong> where an<strong> increase in cardiac output is needed.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to understand the<strong> mechanism of action </strong>of different<strong> inotropic drugs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">INOTROPICS DRUGS</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Beta 1 agonists</span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Dopamine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dobutamine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nor-adrenaline</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Isoprenaline</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol start=\"2\" style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phosphodiesterase inhibitors</span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inamrinone</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Milrinone</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levosimendan</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol start=\"3\" style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cardiac glycosides</span></strong></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"margin-left:40px\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Digoxin</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Digitoxin (withdrawn now)</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 15173,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 43289,
      "choices": [
        {
          "id": 172823,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of HMG-CoA reductase </span></span></span></p>"
        },
        {
          "id": 172824,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of cholesterol absorption in the small intestine </span></span></span></p>"
        },
        {
          "id": 172825,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of bile acid synthesis in the liver </span></span></span></p>"
        },
        {
          "id": 172826,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of lipoprotein lipase activity</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the mechanism of action of ezetimibe for the treatment of hypercholesterolemia?</span></span></span></p>",
      "unique_key": "Q1024668",
      "question_audio": null,
      "question_video": null,
      "map_id": 36015,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Inhibition of cholesterol absorption in the small intestine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ezetimibe</strong> specifically targets the <strong>NPC1L1 (Niemann-Pick C1-Like 1) protein,</strong> which is involved in the<strong> intestinal absorption </strong>of <strong>cholesterol.</strong> By<strong> inhibiting NPC1L1,</strong> <strong>ezetimibe reduces the uptake of cholesterol in the small intestine</strong>, leading to a <strong>decrease in the</strong> <strong>amount of cholesterol delivered to the liver. </strong>This results in a<strong> reduction of hepatic cholesterol stores </strong>and an <strong>increase in clearance of</strong> <strong>cholesterol</strong> from the <strong>blood</strong>; consequently,<strong> LDL cholesterol </strong>levels in the <strong>bloodstream decrease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Inhibition of HMG-CoA reductase:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the mechanism of action for <strong>statins, not ezetimibe. Statins inhibit the rate-</strong>l<strong>imiting step in cholesterol synthesis in the liver.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Inhibition of bile acid synthesis in the liver:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Bile acid sequestrants </strong>work by this mechanism. They bind<strong> bile acids</strong> in the <strong>intestine, </strong>leading to<strong> increased excretion of cholesterol in the feces.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inhibition of lipoprotein lipase activity:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Inhibiting lipoprotein lipase</strong> would prevent the<strong> breakdown of triglycerides, </strong>not cholesterol. This is<strong> not a mechanism</strong> associated with<strong> ezetimibe.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ezetimibe</strong> <strong>reduces LDL cholesterol by inhibiting the absorption of cholesterol</strong> in the small intestine through its action on the<strong> NPC1L1</strong> <strong>protein.</strong></span></span></span></p>",
      "correct_choice_id": 172824,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}